Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching
Executive Summary
Substituting a biosimilar for a reference product is a state issue and outside agency's purview, FDA says.
You may also be interested in...
FDA Considering Biosimilars ‘Guardrails’
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.
Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.
Biologics Transition 'Dead Zone' Could Be Eliminated Under US Senate Bill
Discussion draft includes provision requiring completion of assessments of transitioning NDA applications filed by 23 September, even if review lasts beyond the official 2020 transition date.